{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053979","form_type":"8-K","ticker":null,"cik":"0001693011","company_name":"Inozyme Pharma, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.636693+00:00","generated_at":"2026-06-02T19:02:05.060068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inozyme Pharma Q1 net loss $23.3M ($0.38/sh); cash $166.2M; positive ABCC6 data","bullets":["Net loss $23.3M ($0.38 loss per share) vs $17.4M ($0.40) year ago.","Cash, cash equivalents, and short-term investments $166.2M as of March 31, 2024; expected to fund operations into Q4 2025.","Positive topline safety, immunogenicity, and clinical improvement data for INZ-701 in adults with ABCC6 Deficiency reported in April 2024.","Plan to initiate pivotal trial in pediatric ABCC6 Deficiency in Q1 2025, subject to regulatory review and funding.","Interim data from SEAPORT-1 (calciphylaxis) on track for Q4 2024; ENERGY-1 (ENPP1 infants) interim data expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053979","json":"https://secwatch.observer/filing/0000950170-24-053979.json","markdown":"https://secwatch.observer/filing/0000950170-24-053979.md","text":"https://secwatch.observer/filing/0000950170-24-053979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024053979/0000950170-24-053979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024053979/inzy-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:02:05.060068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8553f9b05d7ef83a7d3eaa7e30567a5323fa64fa","claim":"Inozyme Pharma, Inc. reported the first quarter ended March 31, 2024 results: net income $23.3 million, EPS $0.38 loss per share.","evidence_excerpt":"Net loss was $23.3 million, or $0.38 loss per share, for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024053979/0000950170-24-053979-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$23.3 million"},{"label":"EPS","value":"$0.38 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}